We are live on ! Find out more
AFJKR icon

Aimei Health Technology Right
AFJKR

15 hedge funds and large institutions have $1.01M invested in Aimei Health Technology Right in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more capital inflows, than outflows

Capital inflows: $88.5K | Capital outflows: $32.2K

7% more funds holding

Funds holding: 14 → 15 (+1)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
15
Holders Change
+1
Holders Change %
+7.14%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

AFJKR Hedge Fund Activity: Q2 2024 in Review

15 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Aimei Health Technology Right (AFJKR) for Q2 2024, worth a combined $1.01M — up 12% from $896K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new AFJKR positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Westchester Capital Management (New York), opening a new position worth an estimated $64.7K. The largest seller was Glazer Capital, cutting an estimated $12.1K.

  • 15 institutional investors held Aimei Health Technology Right (AFJKR) as of Q2 2024, up from 14 in Q1 2024.
  • Funds reported $1.01M of Aimei Health Technology Right stock for Q2 2024, up 12% quarter-over-quarter.
  • 1 fund opened new Aimei Health Technology Right positions in Q2 2024 and 0 closed out, a net change of +1 holder.
  • The largest Aimei Health Technology Right buyer in Q2 2024 was Westchester Capital Management (New York), an estimated $64.7K added.
  • The largest Aimei Health Technology Right seller in Q2 2024 was Glazer Capital, an estimated $12.1K sold.

Based on aggregated 13F filings for Q2 2024.